MAM
ANTX icon

Marquette Asset Management’s AN2 Therapeutics ANTX Stock Holding History

Marquette Asset Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-83,206
Closed -$115K – 153
2024
Q4 		$115K Buy
83,206
+18,703
+29% +$22.7K 0.02% 121
2024
Q3 		$69K Buy
+64,503
New +$112K 0.01% 159

Other funds holding ANTX

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $66.2B AUM 46.3% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
AC
Aldebaran Capital Carmel, Indiana $133M AUM 42.18% 1-Year Est. Return

Marquette Asset Management's ANTX Position: Q1 2025 in Review

Marquette Asset Management sold out of AN2 Therapeutics (ANTX) in Q1 2025, closing a stake of 83,206 shares — an estimated $115K sold.

Marquette Asset Management first reported a position in ANTX in Q3 2024 and held it in 2 quarters. The position peaked at $115K in Q4 2024. 37 funds tracked by Wall St. Rank hold ANTX as of Q1 2025.

  • Marquette Asset Management reported no remaining AN2 Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Marquette Asset Management sold 83,206 AN2 Therapeutics shares in Q1 2025, an estimated $115K.
  • Marquette Asset Management first reported a position in AN2 Therapeutics in Q3 2024 and held it in 2 quarters.
  • Marquette Asset Management's AN2 Therapeutics position peaked at $115K in Q4 2024.
  • 37 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2025.

Based on Marquette Asset Management's 13F filing for Q1 2025, filed 9 Apr 2025.